Home › Type 2 Diabetes › South Carolina
Type 2 Diabetes clinical trials in South Carolina
20 studies for Type 2 Diabetes are looking for participants at sites in South Carolina.
Cities in South Carolina
- North Charleston5 studies
- Greenville4 studies
- Mount Pleasant3 studies
- Columbia3 studies
- Myrtle Beach3 studies
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Piedmont Research Partners, LLC, Fort Mill
- Velocity Clinical Research-Gaffney-69046, Gaffney
- Tribe Clinical Research LLC - Greenville, Greenville
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07064473A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Monroe Biomedical Research - Charleston, North Charleston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07783802A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- PanAmerican Clinical Research - Bluffton, Bluffton
- Spartanburg Medical Research, Spartanburg
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07754461A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Medical University of South Carolina, Charleston
RecruitingHealthy volunteers welcome
Ages 55 and older · All sexes · Updated Sep 28, 2026 · NCT06112418A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Accellacare - Mt Pleasant, Mt. Pleasant
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07282600Improving the Collaborative Health of Adult Dyads
- University of South Carolina, Columbia
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05370014A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Bluffton
- AURORA-2 Clinical Site, Clemson
- AURORA-2 Clinical Site, Columbia
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07743450A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
- Monroe Biomedical Research Charleston, North Charleston
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 15, 2026 · NCT07340320A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Coastal Carolina Research Center, North Charleston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07351058A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
- Monroe Biomedical Research, LLC, North Charleston
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 11, 2026 · NCT07668388A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Myrtle Beach
- Research Site, North Charleston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07662213Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
- Velocity Clinical Research, Anderson, Anderson
- Accellacare Charleston, Mt. Pleasant
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07296484A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Research Site, Gaffney
- Research Site, Greenville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07662135AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Piedmont Research Partners, LLC, Fort Mill
- Accellacare US Inc._SC, Mt. Pleasant
- Trial Management Associates, Myrtle Beach
RecruitingPhase 3
Ages 45 and older · All sexes · Updated Sep 1, 2026 · NCT07797335A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
- Research Site, Anderson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT07662044A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
- Research Site, Gaffney
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07606066Specimen and Data Collection in South Carolina Medicaid-Enrolled Patients With Type 2 Diabetes (T2D) and Metabolically Healthy Controls
- Clemson Health Clinic at Orangeburg, Orangeburg
- Clemson Health Clinic at Walhalla, Walhalla
RecruitingObservational studyHealthy volunteers welcomeMentions payment for participants
Ages 40 to 70 · All sexes · Updated Aug 18, 2026 · NCT07731399A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- Prisma Health Pediatric Endocrinology, Columbia
- Prisma Health Midlands, Greenville
RecruitingPhase 3
Ages 10 to 17 · All sexes · Updated Aug 7, 2026 · NCT06739122A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
- Research Site, Myrtle Beach
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07664553CGM for Management of Type 2 Diabetes in Pregnancy
- Prisma Health Greenville Memorial Hospital, Greenville
Recruiting
Ages 18 to 50 · Women · Updated Jun 29, 2026 · NCT06628453From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.